Clinical trial
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure - Efficacy and Safety of Sodium Zirconium Cyclosilicate in Optimizing Mineralocorticoid Receptor Antagonists Therapy in Heart Failure
NCT04789239 is registered in ClinicalTrials.gov with Michael Fu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure - Efficacy and Safety of Sodium Zirconium Cyclosilicate in Optimizing Mineralocorticoid Receptor Antagonists Therapy in Heart Failure
- Lead sponsor
- Michael Fu
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 1, 2021
- Completion date
- December 31, 2025
- Enrollment
- 110 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.